{
    "clinical_study": {
        "@rank": "134421", 
        "arm_group": {
            "arm_group_label": "Treatment (capecitabine)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well capecitabine works in treating patients with advanced\n      or recurrent squamous cell carcinoma of the skin. Drugs used in chemotherapy, such as\n      capecitabine, work in different ways to stop the growth of tumor cells, either by killing\n      the cells or by stopping them from dividing."
        }, 
        "brief_title": "Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin", 
        "condition": [
            "Recurrent Skin Cancer", 
            "Squamous Cell Carcinoma of the Skin"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Skin Neoplasms", 
                "Carcinoma, Squamous Cell", 
                "Carcinoma, Basal Cell", 
                "Carcinoma, Basosquamous"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To establish the objective response rate, using Response Evaluation Criteria in Solid\n      Tumors (RECIST) criteria, to capecitabine in patients with metastatic or\n      unresectable/recurrent squamous cell carcinoma of the skin.\n\n      SECONDARY OBJECTIVES:\n\n      I. To establish the safety profile, progression free and overall survival of capecitabine in\n      this patient population.\n\n      OUTLINE:\n\n      Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14. Courses repeat\n      every 21 days in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have squamous cell carcinoma of the skin; patients with \"unknown\n             primary lesions\" at the time of diagnosis, if metastatic disease present with a\n             history of plausible primary skin site removed in the past, are eligible; for\n             example, patients with squamous cell carcinoma in neck or parotid lymph nodes with no\n             identifiable mucosal primary but with a history of the removal of one or more early\n             stage squamous cell carcinomas of the skin in an anatomically relevant lymphatic\n             drainage region would be eligible\n\n          -  Patients must have measurable disease, defined as at least one lesion that can be\n             accurately measured in at least one dimension >= 10 mm with computed tomography (CT)\n             scan, magnetic resonance imaging (MRI), or calipers by clinical exam\n\n          -  There is no limitation to prior treatments with local, regional, topical or systemic\n             agents except for prior systemic treatment with 5- fluorouracil or prodrugs thereof;\n             prior topical treatment with 5- fluorouracil is permitted; there is no restriction on\n             timing of last treatments as long as patients have recovered from expected toxicities\n             of greater than grade 1 and at least 5 half-lives of the last systemically\n             administered agent have passed\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\n\n          -  Life expectancy of greater than 3 months\n\n          -  Absolute neutrophil count >= 1,000/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Total bilirubin within normal institutional limits or up to 2 x upper limit of normal\n             (ULN) if patient has Gilbert's syndrome (elevated unconjugated bilirubin from\n             decreased UDP glucuronosyltransferase 1 family, polypeptide A1 [UGT1A1] activity)\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 X institutional upper limit of normal or up to 5 X ULN if known to be caused\n             by liver metastases\n\n          -  Creatinine less than 1.3 mg/dL OR creatinine clearance >= 30 mL/min/1.73 m^2 for\n             patients with creatinine levels above institutional normal; note creatinine\n             clearances between 30 and 49 mg/dL necessitate dose modification\n\n          -  Patients must not be candidates for curative locoregional treatments; patients with\n             recurrent locoregional disease following surgery and/ or radiation for which a\n             resection is unacceptably morbid and unlikely to be curative are eligible\n\n          -  Multi gated acquisition scan (MUGA)/echocardiogram must show ejection fraction (EF)\n             >= 50% for patients with a history of coronary artery disease (CAD)/myocardial\n             infarction (MI)/congestive heart failure (CHF) or as clinically indicated (principal\n             investigator [PI] discretion)\n\n        Exclusion Criteria:\n\n          -  Patients who are receiving any other investigational agents or anti-cancer treatments\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to capecitabine\n\n          -  While not excluded, patients taking Coumadin-derivative anticoagulants (warfarin) or\n             phenytoin must have international normalized ratio (INR) or drug levels monitored\n             frequently\n\n          -  Uncontrolled concurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant and lactating women are not eligible for this study\n\n          -  Prior treatment with systemic capecitabine or fluorouracil (5-FU) therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "19", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823679", 
            "org_study_id": "SKIN0016", 
            "secondary_id": [
                "NCI-2013-00710", 
                "26699"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (capecitabine)", 
                "description": "Given PO", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CAPE", 
                    "Ro 09-1978/000", 
                    "Xeloda"
                ]
            }, 
            {
                "arm_group_label": "Treatment (capecitabine)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Alexander D. Colevas", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin", 
        "overall_contact": {
            "email": "rlira@stanford.edu", 
            "last_name": "Ruth Lira", 
            "phone": "650-723-1367"
        }, 
        "overall_official": {
            "affiliation": "Stanford University", 
            "last_name": "Alexander Colevas", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective response rate assessed using RECIST version 1.1criteria", 
            "safety_issue": "No", 
            "time_frame": "9 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823679"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse events will be collected according the study calendar and tabulated for cumulative evaluation.", 
                "measure": "Incidence of grade 3 or greater adverse events assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Kaplan-Meier estimates of overall and progression-free survival rates will be calculated, along with their corresponding 95% confidence intervals.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Kaplan-Meier estimates of overall and progression-free survival rates will be calculated, along with their corresponding 95% confidence intervals.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Kaplan-Meier estimates of overall and progression-free survival rates will be calculated, along with their corresponding 95% confidence intervals.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Kaplan-Meier estimates of overall and progression-free survival rates will be calculated, along with their corresponding 95% confidence intervals.", 
                "measure": "OS", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}